Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.

IF 2 Q3 ONCOLOGY Cancer research communications Pub Date : 2024-11-01 DOI:10.1158/2767-9764.CRC-24-0337
Daniel J Landsburg, Jennifer J D Morrissette, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Elise A Chong, Jakub Svoboda, Ashley Barlev, Adam Bagg, Salvatore F Priore
{"title":"Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.","authors":"Daniel J Landsburg, Jennifer J D Morrissette, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Elise A Chong, Jakub Svoboda, Ashley Barlev, Adam Bagg, Salvatore F Priore","doi":"10.1158/2767-9764.CRC-24-0337","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Genomic features of LBCL that can be detected by clinical laboratory assays may predict for resistance to first-line immunochemotherapy, as well as support the exploration of genomic features as biomarkers of response to therapies which could be offered to patients who experience disease progression.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0337","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: Genomic features of LBCL that can be detected by clinical laboratory assays may predict for resistance to first-line immunochemotherapy, as well as support the exploration of genomic features as biomarkers of response to therapies which could be offered to patients who experience disease progression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新确诊的大 B 细胞淋巴瘤伴有或不伴有后续疾病进展的基因组特征。
基因组分析有可能对确诊为大 B 细胞淋巴瘤 (LBCL) 的患者进行风险分级并为管理提供信息。我们分析了三个公开的患者队列中接受标准免疫化疗的新诊断 LBCL 患者病例,对这些病例进行了荧光原位杂交 (FISH) 和新一代测序 (NGS),以根据疾病进展情况确定基因组改变的频率。对 698 例患者的病例进行了分析,其中 201 例患者在确诊后 24 个月内疾病进展,497 例患者在确诊后 24 个月内疾病未进展。在分析是否存在 MYC 重排和 MYC-BCL2 双重排/双命中,以及所有 3 个队列的 NGS 面板中常见的 15 个基因中预测会导致蛋白质功能改变的变异时,只有 MYC 重排和 TP53 突变与多变量分析中显著较高的疾病进展几率相关。此外,按队列或可用免疫组化方法进行的原发细胞分类进行分析时,疾病进展患者的病例表现出较高的特定基因组改变频率。LBCL病例的单个基因组特征可预测接受标准疗法治疗的新诊断患者的疾病进展情况,也可根据地理区域和/或原代细胞状态预测疾病进展病例的高发情况。这些新发现支持将基因组特征作为生物标记物来评估经历疾病进展的LBCL患者对特定疗法的反应,从而发现更有效的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging Agent. High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis. Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma. Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1